Russian ruble's depreciation hits Richter
Hungarian pharmaceutical drug producer Richter will release its earnings report for Q3 this week. The analysts project a major decline in key profits, portfolio.hu reported. The main reason for this is depreciation of Russia’s ruble in the third quarter of 2014. The ruble depreciated 5% to the HUF in the the third quarter of 2015.
The exchange rate of the ruble is one of the most important factors affecting Richter’s profitability. Russia has been the company’s largest market for a long time and contributes more than 30% of group revenues.
Speaking of specific markets, sales to Russia and Ukraine could be of a significant importance at this time. Following the previous quarterly earnings report, Richter lowered its estimates for both countries for 2014. Analysts predict Russian sales revenues will disappoint again, especially as the base period showed a relatively strong performance. Conversely, Western Europe fared relatively well in the third quarter.
Analysts agree that Richter will report 61.5% gross margin for Q3, which would mark a 1% year-on-year deterioration. The detoriation is mainly attributed to the easing of the ruble.
As for Richter’s EBIT, the market forecasts a large year-on-year contraction of about 30%, partly as a consequence of the ruble's depreciation. Analysts also likely factored in a further rise in operating costs, since clinical trials continue to absorb large funds; add to that the expansions in China and Latin America.
The market sees Richter’s Q3 operating margin at around 11%, decreasing about 4% compared to the same period in 2013.
Richter’s net profit is seen even more drastically down in the annual comparison than its EBIT and it is also likely that the market expects negative financial income.The end-quarter EUR/HUF exchange rate was similar to the end-Q2 figure. Consequently, the key factor here was the ruble as well. The HUF was around 6% stronger to the RUB at the end of September than at the end of June, which could have led to unrealised losses at the revaluation of assets booked in RUB.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.